Richard Lock

Summary

Affiliation: University of New South Wales
Country: Australia

Publications

  1. doi request reprint Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program
    Richard B Lock
    Children s Cancer Institute Australia for Medical Research, Randwick, NSW, Australia
    Pediatr Blood Cancer 60:E42-5. 2013
  2. pmc Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program
    Richard B Lock
    Lowy Cancer Research Centre, Randwick, NSW, Australia
    Pediatr Blood Cancer 58:916-23. 2012
  3. pmc Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer
    Hernan Carol
    Leukaemia Biology Program, Children s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW, Randwick, NSW 2031, Australia
    Cancer Chemother Pharmacol 68:1291-304. 2011
  4. pmc Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemia
    Amy L Samuels
    Division of Children s Leukaemia and Cancer Research, Telethon Institute for Child Health Research, Perth, Western Australia
    BMC Genomics 11:256. 2010
  5. ncbi request reprint Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program
    Richard Lock
    Children s Cancer Institute Australia for Medical Research, Randwick, NSW, Australia
    Pediatr Blood Cancer 50:1181-9. 2008
  6. ncbi request reprint In vivo models of childhood leukemia for preclinical drug testing
    Petra S Bachmann
    Children s Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, Australia
    Curr Drug Targets 8:773-83. 2007
  7. doi request reprint Induction of vascular endothelial growth factor secretion by childhood acute lymphoblastic leukemia cells via the FLT-3 signaling pathway
    Ana Markovic
    Children s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, University of New South Wales, Sydney, New South Wales, Australia
    Mol Cancer Ther 11:183-93. 2012
  8. pmc Evaluation of the NOD/SCID xenograft model for glucocorticoid-regulated gene expression in childhood B-cell precursor acute lymphoblastic leukemia
    Vivek A Bhadri
    Children s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, University of New South Wales, Randwick, NSW 2031, Australia
    BMC Genomics 12:565. 2011
  9. pmc Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program
    Hernan Carol
    Children s Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia
    Pediatr Blood Cancer 53:1255-63. 2009
  10. doi request reprint Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program
    Hernan Carol
    Children s Cancer Institute Australia for Medical Research, Randwick, NSW, Australia
    Pediatr Blood Cancer 61:245-52. 2014

Collaborators

Detail Information

Publications38

  1. doi request reprint Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program
    Richard B Lock
    Children s Cancer Institute Australia for Medical Research, Randwick, NSW, Australia
    Pediatr Blood Cancer 60:E42-5. 2013
    ..Administered as single agents, Hsp90 inhibitors examined by the PPTP have shown limited evidence for a therapeutic window against both solid tumor and leukemia pediatric preclinical models...
  2. pmc Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program
    Richard B Lock
    Lowy Cancer Research Centre, Randwick, NSW, Australia
    Pediatr Blood Cancer 58:916-23. 2012
    ..The centromere kinesin motor protein CENP-E plays a crucial role in mitosis, and is an appealing molecular target in cancer. GSK923295A is an allosteric inhibitor of CENP-E that is undergoing clinical evaluation...
  3. pmc Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer
    Hernan Carol
    Leukaemia Biology Program, Children s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW, Randwick, NSW 2031, Australia
    Cancer Chemother Pharmacol 68:1291-304. 2011
    ..To gain a greater understanding of the potential of the Aurora kinase A inhibitor MLN8237 in the treatment of pediatric malignancies...
  4. pmc Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemia
    Amy L Samuels
    Division of Children s Leukaemia and Cancer Research, Telethon Institute for Child Health Research, Perth, Western Australia
    BMC Genomics 11:256. 2010
    ..However, for this model to be effective for studying engraftment and therapy responses at the whole genome level, careful molecular characterisation is essential...
  5. ncbi request reprint Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program
    Richard Lock
    Children s Cancer Institute Australia for Medical Research, Randwick, NSW, Australia
    Pediatr Blood Cancer 50:1181-9. 2008
    ....
  6. ncbi request reprint In vivo models of childhood leukemia for preclinical drug testing
    Petra S Bachmann
    Children s Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, Australia
    Curr Drug Targets 8:773-83. 2007
    ....
  7. doi request reprint Induction of vascular endothelial growth factor secretion by childhood acute lymphoblastic leukemia cells via the FLT-3 signaling pathway
    Ana Markovic
    Children s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, University of New South Wales, Sydney, New South Wales, Australia
    Mol Cancer Ther 11:183-93. 2012
    ....
  8. pmc Evaluation of the NOD/SCID xenograft model for glucocorticoid-regulated gene expression in childhood B-cell precursor acute lymphoblastic leukemia
    Vivek A Bhadri
    Children s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, University of New South Wales, Randwick, NSW 2031, Australia
    BMC Genomics 12:565. 2011
    ..Leukemia cells were harvested from mice spleens at 0, 8, 24 or 48 hours thereafter, and gene expression analyzed on Illumina WG-6_V3 chips, comparing all groups to time 0 hours...
  9. pmc Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program
    Hernan Carol
    Children s Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia
    Pediatr Blood Cancer 53:1255-63. 2009
    ..Here we report the activity of ispinesib against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP)...
  10. doi request reprint Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program
    Hernan Carol
    Children s Cancer Institute Australia for Medical Research, Randwick, NSW, Australia
    Pediatr Blood Cancer 61:245-52. 2014
    ..Quisinostat was selected for clinical development as it showed prolonged pharmacodynamic effects in vivo and demonstrated improved single agent antitumoral efficacy compared to other analogs...
  11. ncbi request reprint Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies
    Natalia L M Liem
    Children s Cancer Institute Australia for Medical Research, Sydney, Australia
    Blood 103:3905-14. 2004
    ..As such, they provide powerful experimental models to prioritize new therapeutic strategies for future clinical trials...
  12. ncbi request reprint The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse
    Richard B Lock
    Children s Cancer Institute Australia for Medical Research School of Paediatrics, University of New South Wales, Australia
    Blood 99:4100-8. 2002
    ....
  13. ncbi request reprint TCL1: a new drug target in lymphoid and germ-cell malignancies?
    Richard B Lock
    Children s Cancer Institute Australia for Medical Research, NSW 2031, Randwick, Australia
    Int J Biochem Cell Biol 35:1614-8. 2003
    ..This review is focused on the current state of knowledge of TCL1 and the medical implications of its discovery...
  14. ncbi request reprint Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor
    Petra S Bachmann
    Children s Cancer Institute Australia for Medical Research, PO Box 81, High Street, Randwick, NSW 2031, Australia
    Blood 105:2519-26. 2005
    ..These results show that dexamethasone resistance in BCP ALL xenografts occurs downstream of ligand-induced nuclear translocation of the GR, but upstream of Bim induction...
  15. ncbi request reprint Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia
    Petra S Bachmann
    Children s Cancer Institute Australia for Medical Research, The University of New South Wales, Sydney, Australia
    Cancer Res 67:4482-90. 2007
    ....
  16. ncbi request reprint Initial testing of cisplatin by the pediatric preclinical testing program
    Mimi Tajbakhsh
    Children s Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia
    Pediatr Blood Cancer 50:992-1000. 2008
    ..Cisplatin is one of the most widely used drugs for the treatment of solid tumors in adults and children. Here, we report the activity of cisplatin against the PPTP panels of childhood cancer xenografts...
  17. ncbi request reprint Xenograft models for the preclinical evaluation of new therapies in acute leukemia
    Erwin M Lee
    Children s Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, Australia
    Leuk Lymphoma 48:659-68. 2007
    ..This review summarizes the recent developments and considerations in the use of xenograft models of acute lymphoblastic leukemia, acute myeloid leukemia, and acute promyelocytic leukemia for the preclinical testing of new therapies...
  18. pmc Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program
    Hernan Carol
    Children s Cancer Institute Australia for Medical Research, Randwick, NSW, Australia
    Pediatr Blood Cancer 55:1329-37. 2010
    ....
  19. doi request reprint Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition
    Petra S Bachmann
    Children s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia
    Blood 116:3013-22. 2010
    ..These findings provide a novel therapeutic strategy to reverse glucocorticoid resistance and improve outcome for high-risk pediatric ALL...
  20. ncbi request reprint Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia--an in vivo study
    Nicole M Verrills
    Children s Cancer Institute Australia for Medical Research, Randwick, NSW, Australia
    Proteomics 6:1681-94. 2006
    ....
  21. doi request reprint ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer
    Julie A I Thoms
    Lowy Cancer Research Centre and the Prince of Wales Clinical School, University of New South Wales, Sydney, Australia
    Blood 117:7079-89. 2011
    ..Taken together, these data illustrate that ERG promotes T-ALL and that failure to extinguish activity of stem cell enhancers associated with regulatory transcription factors such as ERG can contribute to the development of leukemia...
  22. ncbi request reprint Inactivation of p16INK4a, with retention of pRB and p53/p21cip1 function, in human MRC5 fibroblasts that overcome a telomere-independent crisis during immortalization
    Lisa M Taylor
    Children s Cancer Institute Australia for Medical Research, Randwick, New South Wales 2031
    J Biol Chem 279:43634-45. 2004
    ..Overall, these results implicate the inactivation of p16INK4a as a critical event for overcoming telomere-independent crisis, immortalizing MRC5 fibroblasts and overcoming ras-induced premature senescence...
  23. doi request reprint The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs
    Laura M High
    Children s Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, New South Wales, Australia
    Mol Pharmacol 77:483-94. 2010
    ..Overall, this study supports the inclusion of the clinical derivative of ABT-737, ABT-263 (for structure, see Cancer Res 68:3421-3428, 2008), into clinical trials against relapsed/refractory pediatric ALL...
  24. pmc Initial testing of topotecan by the pediatric preclinical testing program
    Hernan Carol
    Children s Cancer Institute Australia for Medical Research, Randwick, NSW, Australia
    Pediatr Blood Cancer 54:707-15. 2010
    ..Topotecan was evaluated against the Pediatric Preclinical Testing Program (PPTP) tumor panels as part of a validation process for these preclinical models...
  25. ncbi request reprint Reduced immunogenicity of first-trimester human fetal pancreas
    Kerstin Brands
    Diabetes Transplant Unit, The Prince of Wales Hospital and The University of New South Wales, Sydney, New South Wales 2031, Australia
    Diabetes 57:627-34. 2008
    ..Tissue obtained from earlier stages might prove to be immune privileged, as has been shown for other tissues...
  26. ncbi request reprint FLT-3: a new focus in the understanding of acute leukemia
    Ana Markovic
    Children s Cancer Institute Australia for Medical Research, PO Box 81, High Street, Randwick, NSW 2031, Australia
    Int J Biochem Cell Biol 37:1168-72. 2005
    ....
  27. ncbi request reprint siRNA targeting the IRF2 transcription factor inhibits leukaemic cell growth
    Ailyn Choo
    Children s Cancer Institute Australia for Medical Research, Randwick, Australia
    Int J Oncol 33:175-83. 2008
    ..In contrast to these results, siIRF2 targeting did not affect normal haematopoietic stem/progenitor cell growth. These results indicate the potential utility of IRF2 inhibition as a therapeutic approach to cancer...
  28. ncbi request reprint Insight into the selectivity of arsenic trioxide for acute promyelocytic leukemia cells by characterizing Saccharomyces cerevisiae deletion strains that are sensitive or resistant to the metalloid
    Pierre J Dilda
    UNSW Cancer Research Centre, University of New South Wales, Sydney 2052, Australia
    Int J Biochem Cell Biol 40:1016-29. 2008
    ..These findings demonstrate the usefulness of the S. cerevisiae deletion set and show that the selectivity of arsenic trioxide for APL cells relates, at least in part, to impaired osmoregulation and control of uptake of the drug...
  29. ncbi request reprint A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts
    Vivienna Ong
    Children s Cancer Institute Australia, PO Box 81, High St, Randwick 2031, NSW, Australia
    J Pharmacol Exp Ther 324:434-42. 2008
    ..These results indicate that the balance between polymerized and nonpolymerized tubulin may be an important determinant of response to Vinca alkaloid-based chemotherapy regimens in childhood ALL...
  30. ncbi request reprint Testing of new agents in childhood cancer preclinical models: meeting summary
    Peter J Houghton
    St Jude Children s Research Hospital, Memphis, Tennessee 38101, USA
    Clin Cancer Res 8:3646-57. 2002
    ..This report is a synthesis of the workshop's presentations and discussions...
  31. ncbi request reprint Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo
    Min H Kang
    Developmental Therapeutics Program, Childrens Hospital Los Angeles and University of Southern California Institute for Pediatric Clinical Research, Los Angeles, CA 90027, USA
    Blood 110:2057-66. 2007
    ..Combining VXL with a BH3-mimetic warrants clinical investigation in ALL at relapse and potentially in chemotherapy-resistant ALL subgroups...
  32. ncbi request reprint Initial testing of dasatinib by the pediatric preclinical testing program
    E Anders Kolb
    The Children s Hospital at Montefiore, Bronx, New York, USA
    Pediatr Blood Cancer 50:1198-206. 2008
    ..Dasatinib, a dual inhibitor of the src and abl tyrosine kinases, was recently approved by the Federal Drug Administration for the treatment of imatinib mesylate-resistant chronic myeloid leukemia...
  33. doi request reprint Molecular characterization of the pediatric preclinical testing panel
    Geoffrey Neale
    Hartwell Center of Bioinformatics and Biotechnology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Clin Cancer Res 14:4572-83. 2008
    ..Identifying novel therapeutic agents for the treatment of childhood cancers requires preclinical models that recapitulate the molecular characteristics of their respective clinical histotypes...
  34. ncbi request reprint RNA loading of leukemic antigens into cord blood-derived dendritic cells for immunotherapy
    Andy K W Hsu
    Bone Marrow Transplant Team, Biotherapy Program, Mater Medical Research Institute, South Brisbane, Queensland, Australia
    Biol Blood Marrow Transplant 12:855-67. 2006
    ..This significant improvement in DC transfection represents an important step forward in the development of immunotherapy protocols for the treatment of malignancy...
  35. doi request reprint A xenograft model of infant leukaemia reveals a complex MLL translocation
    Michelle J Henderson
    Br J Haematol 140:716-9. 2008
  36. ncbi request reprint Preclinical testing of antileukemic drugs using an in vivo model of systemic disease
    Richard B Lock
    Childern s Cancer Institute Australia for Medical Research, South Australia, Sydney
    Methods Mol Med 111:323-34. 2005
    ..These experimental models will be useful for the preclinical evaluation of novel therapies...
  37. ncbi request reprint p53 determines multidrug sensitivity of childhood neuroblastoma
    Chengyuan Xue
    Children s Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia
    Cancer Res 67:10351-60. 2007
    ....
  38. ncbi request reprint Immunodetecting members of the Bcl-2 family of proteins
    Richard B Lock
    Children s Cancer Institute Australia for Medical Research, South Australia, Sydney
    Methods Mol Med 111:83-96. 2005
    ..In addition, the methodology describes how conformational changes can be observed by immunofluorescence and immunoprecipitation, and how subcellular redistribution of Bcl-2 homologs can be followed...